Unpredicted adverse reaction to omalizumab

Jandus, P; Hausmann, O; Haeberli, G; Gentinetta, T; Mueller, U; Helbling, A (2011). Unpredicted adverse reaction to omalizumab. Journal of investigational allergology & clinical immunology, 21(7), pp. 563-6. Barcelona: Esmon Publicidad

Full text not available from this repository. (Request a copy)

Despite promising reports of the use of omalizumab as add-on therapy in patients with systemic mastocytosis and recurrent anaphylaxis during specific venom immunotherapy (VIT), unpredicted adverse effects may lead to therapy failure. We present the case of a patient with systemic mastocytosis and Hymenoptera venom allergy who was administered omalizumab as add-on therapy to improve VIT tolerability after repeated severe adverse reactions despite H1/H2-antihistamine prophylaxis. We describe an unexpected discontinuation of omalizumab following successful initiation of VIT in a patient with systemic mastocytosis, with subsequent lack of tolerability of VIT. An interesting aspect of this case is the correlation of basophil activation test results with both clinical tolerability and VIT intolerance.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Hausmann, Oliver, Helbling, Arthur




Esmon Publicidad




Factscience Import

Date Deposited:

04 Oct 2013 14:26

Last Modified:

05 Dec 2022 14:07

PubMed ID:


Web of Science ID:



https://boris.unibe.ch/id/eprint/9325 (FactScience: 215025)

Actions (login required)

Edit item Edit item
Provide Feedback